BackGlenmark gets tentative FDA nod for anti-acne Epiduo gel in US
Epiduo gel recorded sales of around $351.8 million in the year to February, according to IMS Health sales data
Premium
Hyderabad: Glenmark Pharmaceuticals Ltd on Friday said it had received tentative approval from the US Food and Drug Administration (FDA) for the generic version of US-based Galderma Laboratories LP’s Epiduo gel, used in the treatment of acne.
Epiduo gel is generically known as adapalene and benzoyl peroxide gel.
According to IMS Health sales data, for the 12 months to February 2016, Epiduo gel recorded sales of around $351.8 million.
Glenmark’s current portfolio consists of 112 products authorized for distribution in the US. It has 58 abbreviated new drug application (ANDAs) awaiting FDA approval.
On Friday, shares of Glenmark gained 1.48% to end trading at ₹ 830.60 on BSE, while the benchmark Sensex declined 0.01% to 25,606.62 points.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
